Short answer
Merck & Co. (MRK) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.2). Q2 2026 earnings released August 4, 2026, with results in Exhibit 99.1.
Merck & Co. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 earnings released August 4, 2026, with results in Exhibit 99.1
- Supplemental information in Exhibit 99.2, providing additional investor context beyond the press release
- Exhibits excluded from Section 18 “filed” status, limiting associated Exchange Act liability
Item EX-99.1 · Exhibit EX-99.2
- Q2 sales reached $16.6B, up 5% or 4% ex-FX, led by KEYTRUDA/QLEX at $8.4B and WINREVAIR growth of 75%
- GAAP loss per share was $0.54 versus $1.76 earnings, driven by the $2.31-per-share Terns acquisition charge
- Terns acquisition adds MK-4208, an investigational BCR::ABL1 inhibitor with FDA Breakthrough Therapy designation
- 2026 sales outlook raised to $66.3B-$67.3B from $65.8B-$67.0B, signaling stronger operating momentum
- Non-GAAP EPS outlook cut to $2.66-$2.76 from $5.04-$5.16, reflecting Terns and Cidara acquisition charges totaling $5.93 per share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Merck & Co. 8-K filings
Get the next MRK 8-K as it lands
Follow MRK for push alerts, or ask the research agent what this filing means.